Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated | ARWR Message Board Posts

Arrowhead Pharmaceuticals, Inc.

  ARWR website

ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10005 of 10025  at  6/17/2019 2:10:58 PM  by

biochemyst


 In response to msg 10004 by  Aspector
view thread

Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA

 It's clear with the Amgen statements regarding siRNAs that they appear not only happy, but ecstatic with this new modality.  This paper further strengthens their resolve at investigating siRNA as "an emerging" modality.  Remember, they recently published excellent work on delivery to hepatocytes using a monoclonal antibody to bind ASGPR instead of GalNac, and it worked far better than expected.  That result opens up many more tissues to RNAi drugs.  Amgen is clearly highly interested in RNAi.
 
ARWR seems to have assembled the ideal portfolio for Amgen...  Lp(a) is sold to Amgen already, but 2 powerhouse cardiovascular drugs ANG2 and APOC3 have been administered in PI, to which Anazalone has stated "we are on fire right now" and followed that up with "ANG3 will be a PCSK9 killer."  I don't see a reason that Amgen would not want those targets, and it potentially is being laid out for a buyout from Amgen.  Consider the only target sold off is HBV, which Amgen is not pursuing, it becomes a reasonable assumption that there is the potential for talks of greater importance, all the way through a full buyout where Amgen can bolt on RNAi.  
 
-bio 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 9     Views: 245
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
10007 Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA Aspector 1 6/18/2019 7:27:52 AM


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...